TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05951439

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CRE + HMB
Description: 3 g/day of CRE and 3 g/day of HMB

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CRE + GAA
Description: 3 g/day of CRE and 3 g/day of GAA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 g/day of inulin
Study: NCT04766047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Administration of dexmedetomidine intraoperatively
Study: NCT05772481

Intervention type: OTHER
Intervention: PET-MRI
Description: Each patient will have a pre-treatment PET-MRI (PET-MRI 1) within 21 days before the start of treatment.~Induction chemotherapy may be performed at another center than the investigating center.~After 3 cycles of induction chemotherapy and before the 4th cycle, a second PET MRI (PET MRI 2) will be performed. In patients who have received less than 3 cycles of induction chemotherapy, this mid-therapy PET-MRI will not be performed.~A 3rd PET-MRI will be performed prior to radiation therapy (PET-MRI 3). A final MRI PET (MRI PET 4) will take place before surgery.~A total of 4 PET MRI scans will be performed.
Study: NCT06079424

Intervention type: OTHER
Intervention: high-precision carotid echo-tracking
Description: evaluation of vascular aging parameters and baroreflex sensitivity
Study: NCT06050655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual aligners
Description: orthodontic treatment with lingual aligners
Study: NCT06509750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carob-meal
Description: A meal with carob-beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-carob-meal
Description: A meal with orange-beverage
Study: NCT04902703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Sargramostim is a granulocyte macrophage colony stimulating factor that will be administered at a dose of 250 mcg/m2 per day subcutaneously, 5 days/week, for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline - placebo comparator
Description: Saline will be administered subcutaneously, 5 days/week, for 24 weeks
Study: NCT05393271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered
Study: NCT05481723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: noradrenaline and vascular filling
Description: In the control group, the haemodynamic management of the patients is done according to usual practice by maintaining blood pressure with noradrenaline and optimising stroke volume with vascular filling.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary ultrasound after vascular filling
Description: In the interventional group, intraoperative haemodynamic management is based on an algorithm that includes measurement of the number of B-lines appearing on pulmonary ultrasound after vascular filling. Monitoring of the stroke volume will also be performed in this group in order to stop the vascular filling if the ESV does not increase by more than 10%.
Study: NCT06488521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Complarate
Description: Complarate solution, a subcutaneous injection at a single dose of 162 mg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Actemra®
Description: Actemra® solution, subcutaneous injection at a single dose of 162 mg.
Study: NCT05269537

Intervention type: RADIATION
Intervention: Transthoracic Echocardiography
Description: Measurement of cardiac output in supine position with left lateral tilt at baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection

Intervention type: PROCEDURE
Intervention: Spinal Anesthesia
Description: Performed at the L3-L4 or L4-L5 interspace using 25-gauge spinal needle

Intervention type: DRUG
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space

Intervention type: DRUG
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 μg will be administered in the subarachnoid space

Intervention type: DRUG
Intervention: Crystalloid Coload 1000 mL
Description: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection

Intervention type: PROCEDURE
Intervention: Cesarean Delivery
Description: Lower segment cesarean section using the Pfannenstiel incision and uterine exteriorization

Intervention type: DRUG
Intervention: Intravenous Ephedrine
Description: Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.

Intervention type: DRUG
Intervention: Oxytocin
Description: Intravenous oxytocin 10 U in 500 mL Ringer acetate will be administered over 30 minutes starting immediately after delivery of the fetus
Study: NCT05542732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioWatch 287-2
Description: CardioWatch 287-2 (CW2 Test Device or CW2). This medical device is based on the precursor CardioWatch 287-1 approved by EU-MDR under number 20M00011CRT01, CW2 has two red, two infrared and two green LEDs, and two photosensors compared to its precursor.
Study: NCT05233150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PriCARE/CARIÑO
Description: PriCARE/CARIÑO is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE/CARIÑO uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE/CARIÑO includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. CARIÑO is the culturally adapted version of PriCARE for Spanish speaking participants.
Study: NCT05563012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimal Injection
Description: Sintilimal (200mg) will be given i.v. on day 1 of each 3-week cycle.
Study: NCT05994911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: The application is planned as 8 sessions and one session per week. Each session corresponds to one lesson hour and is approximately 30-40 minutes. In the content of the application, the individual's attention, mind, attitude, intention, thought; It has basic concepts such as the separation and merging process of thoughts in our minds, the deep processes of awareness, staying in the moment, values, focusing process, self-compassion, integration of awareness with other situations in life, meditation practices developed with practice, and the content summarized around these concepts. It is a program that tries to enable individuals to focus on the moment they live in, within the framework of these basic concepts. The program is divided into session titles such as Introduction to Mindfulness, Mind Awareness, Body Awareness, Emotion and Behavior Awareness, Self Compassion, Stress Awareness, Eating Awareness.
Study: NCT05895890

Intervention type: GENETIC
Intervention: Sequential sampling (stool, saliva, serum) .
Description: Sequential sampling (stool, saliva, serum) prior to the occurrence of AAH episodes in heavy drinking patients to identify protective or deleterious profiles.
Study: NCT04778059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USB002
Description: USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).
Study: NCT06365008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+irinotecan+leucovorin folinate+fluorouracil
Description: sintilimab 3mg/kg for patients with body weight\<60kg or 200mg for patients with body weight ≥ 60kg, plus irinotecan 180mg/m2 intravenous infusion, leucovorin folinate 400mg/m2 intravenous infusion and fluorouracil 400mg/m2 intravenous injection followed by 2400mg/m2 intravenous infusion for 48 hours, repeated every two weeks.
Study: NCT05882838

Intervention type: OTHER
Intervention: Myofascial Pain Syndrome Knowledge and Awareness Questionnaire
Description: Myofascial Pain Syndrome Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
Study: NCT05311228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Powder
Description: Azithromicyn intravena for 14 days
Study: NCT06342219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback Mindfulness
Description: The participants will use a portable EEG headband (MUSE) which is a noninvasive tool for collecting EEG data. They will receive real-time EEG data given an audio feedback while doing their daily mindfulness practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Task
Description: The participants in this arm will use the portable EEG while listening to an audiobook. They will receive a summary of their brain activities after task completion on each day.
Study: NCT04660500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD Drivers Using AV Technologies On-road
Description: All drives will include events to assess the impact of in-vehicle information systems (IVIS) and advanced driver assistance systems (ADAS) on the driving performance (driving errors) of drivers with PD. For IVIS the investigators will include options to assess errors with lane maintenance (with and without the lane departure warning system) and signaling (with and without blind spot detection). For ADAS the investigators will include conditions to assess errors in speeding (with and without adaptive cruise control) and lane exceedances (with and without lane keeping assist).
Study: NCT06317311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab is administered via intravenous (IV) infusion at a dose of 500 milligram (mg) for first 6 cycles (each cycle is of 21 days) followed by 1,000 mg from cycle 7 (each cycle is of 42 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is administered IV at a dose of Area under the concentration time curve (AUC) 5 milligram\*millilitre/ minute (mg•mL/min) for cycles 1 to 6 (each cycle is of 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is administered IV at a dose of 175 milligram per meter square (mg/m2) for cycles 1 to 6 (each cycle is of 21 days)
Study: NCT05019846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Embonate
Description: single administration before SRT starting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg
Description: 1 dose each day, 7 days before LHRH until 10 days after LHRH administration
Study: NCT06342011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet group
Description: Patients in the intervention group were given AID knowledge education, and patients were asked to pay attention to the anti-inflammatory diet wechat mini program developed by the researchers to teach patients how to use it, including the selection of anti-inflammatory diet, unsuitable anti-inflammatory diet, diet alarm clock, diet notes and other related functions. The missionary patients insisted on AID until reexamination 8 weeks later.
Study: NCT06416787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: IBI355 7.5mg/kg Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: IBI355 7.5mg/kg Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: IBI355 7.5mg/kg Q4W
Study: NCT05156216

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Knowledge and beliefs about the condition and its management influences patient behavioural intentions, including treatment choices. Thus, patient education may play an important role in facilitating desirable behaviours with the aim of education being to develop accurate beliefs about treatment options and empower people to choose wisely for their current needs and circumstances.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Knowledge and beliefs about the condition and its management influences patient behavioural intentions, including treatment choices. Thus, patient education may play an important role in facilitating desirable behaviours with the aim of education being to develop accurate beliefs about treatment options and empower people to choose wisely for their current needs and circumstances.
Study: NCT06416787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: IBI355 7.5mg/kg Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 1mg/kg Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 1mg/kg Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 1mg/kg Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 1mg/kg Q4W
Study: NCT05583734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portomar(TM) Device
Description: Portomar(TM) access device for bone marrow biopsy
Study: NCT05288595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Plus Instrument
Description: Miltenyi Biotec's CliniMACS Plus Instrument is to be used to TCRαβ CD19 deplete products utilized in this protocol. The CliniMACS Plus is an automated cell separation platform which is functionally closed, maintaining a sterile system for cell depletion and enrichment utilizing a magnetic separation column. Reagents and supplies are to be used for research only but are manufactured and tested under a quality system certified to ISO 13485. Should CD34 selection be required to augment stem cell dose, Miltenyi Biotec's CliniMACS® Plus CD34 Reagent System is FDA approved as a Humanitarian Use Device (HUD). The approved indication was the treatment of patients with acute myeloid leukemia (AML) undergoing myeloablative transplant from matched related allogeneic donors. The CliniMACS® Plus reagent system was approved to obtain an enriched CD34+ cell population for hematopoietic reconstitution without the need for GVHD prophylaxis.
Study: NCT05824052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ozone injection
Description: Ozone injection is a process where ozone gas is injected into a substance or system for various purposes. Ozone gas (O3) is a highly reactive form of oxygen that can be generated through the use of specialized ozone generators. Ozone injection can be used in a variety of applications, including water treatment, air purification, and medical therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ozone injection
Description: Ozone injection is a process where ozone gas is injected into a substance or system for various purposes. Ozone gas (O3) is a highly reactive form of oxygen that can be generated through the use of specialized ozone generators. Ozone injection can be used in a variety of applications, including water treatment, air purification, and medical therapy.
Study: NCT04790162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heartfulness Meditation
Description: Heartfulness meditation with a trainer provided virtually
Study: NCT04477590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Description: A group will train 30 min after taking their habitual dose of medicine (MEDICATED train) while another group will train after taking a placebo (NON-MEDICATED train) and will receive their medication after training.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Description: A group will train 30 min after taking their habitual dose of medicine (MEDICATED train) while another group will train after taking a placebo (NON-MEDICATED train) and will receive their medication after training.
Study: NCT05161455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Description: we would like to measure the effect of PRF on soft and hard tissue healing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Description: we would like to measure the effect of PRF on soft and hard tissue healing

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich fibrin
Description: we would like to measure the effect of PRF on soft and hard tissue healing

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: platelet rich fibrin
Description: we would like to measure the effect of PRF on soft and hard tissue healing
Study: NCT05503602

Intervention type: OTHER
Group type: OTHER
Intervention: Classical Physiotherapy
Description: Only classical physiotherapy application, 5 sessions per week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM Technique Application
Description: Instrument-assisted soft tissue mobilization application 2 sessions per week together with 3 sessions of classical physiotherapy per week for 4 weeks. IASTM application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Roller Technique Application
Description: 2 sessions of foam roller technique per week along with 3 sessions of classical physiotherapy per week for 4 weeks. Foam roller application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
Study: NCT04482660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with 18F-RO6958948
Description: tau PET ()
Study: NCT06104761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Release group
Description: i will make release for these muscles ( upper trapizius , levator scapulae , strenomastoid ) in addition to sub occipital fascia , then I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).

Intervention type: OTHER
Group type: OTHER
Intervention: strength exercises and stretching for upper crossed syndrome
Description: I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strength exercises and stretching for upper crossed syndrome
Description: I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
Study: NCT05796284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast pressure relief intervention at the end of pregnancy
Description: When teaching pregnant women, the researchers will use tablet computers and models to explain the operation of breast combing and acupressure one-on-one, and use the model to demonstrate. Emphasis on breast grooming during pregnancy, twice a day, once in the morning and evening, 5 minutes on one breast each time, 10 minutes on both sides; strengthen breast grooming and acupressure after delivery. The first breast combing, 5 minutes on one breast each time, and 10 minutes on both sides 4 to 6 times a day. After combing, according to expert advice, massage the 6 acupoints around the breast for 5-10 seconds, and then use hand expressing or breastfeeding to discharge the milk .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Cases in the routine care group received routine prenatal care and guidance during weekly outpatient checkups, and routine postpartum care and guidance after delivery.
Study: NCT06575699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectus sheath block
Description: bilateral rectus sheath block under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side deposited between the rectus abdomens muscle and the posterior rectus sheath.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural Analgesia
Description: Low thoracic Epidural Analgesia.
Study: NCT05796284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Cases in the routine care group received routine prenatal care and guidance during weekly outpatient checkups, and routine postpartum care and guidance after delivery.
Study: NCT06575699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 133 mg liposomal bupivacaine per side for rectus sheath block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 20 mL bupivacaine 0.25% per side for rectus sheath block